Post-Transplant Lymphoproliferative Disorder
Associated Genetic Biomarkers
NCI Definition: Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001) 
Post-transplant lymphoproliferative disorders most frequently harbor alterations in TP53, MCL1, and CBL .
TP53 c.217-c.1178 Missense, TP53 R248Q, TP53 Mutation, TP53 Missense, and TP53 Exon 7 Mutation are the most common alterations in post-transplant lymphoproliferative disorder .
There are 12 clinical trials for post-transplant lymphoproliferative disorder, of which 9 are open and 3 are completed or closed. Of the trials that contain post-transplant lymphoproliferative disorder as an inclusion criterion, 1 is early phase 1 (1 open), 9 are phase 2 (7 open), and 2 are phase 3 (1 open).
EBV, MS4A1, and Epstein-Barr are the most frequent gene inclusion criteria for post-transplant lymphoproliferative disorder clinical trials .
Rituximab, tabelecleucel, and bendamustine are the most common interventions in post-transplant lymphoproliferative disorder clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.